Our current understanding of adult ADHD.
Year: 2014
Type: article
Abstract: FUNDING:No funding was provided for the preparation of this article.
FINANCIAL DISCLOSURES:Dr. Targum has received consultation fees, retainers, or vendor grants from the following pharmaceutical sponsors within the past three years: Acadia Pharmaceuticals, Acumen, Alcobra, Alkermes Inc., AstraZeneca, BioMarin, BrainCells Inc., CeNeRx, Civitas, Eli Lilly and Company, EnVivo (Forum) Pharmaceuticals, Euthymics, Functional Neuromodulation Inc, Intracellular Therapies Inc., Ironwood Pharmaceuticals, Johnson & Johnson PRD, Methylation Sciences Inc., Mitsubishi Tanabe, NeoSync, Neurim, Novartis Pharmaceuticals, Nupathe, One Carbon Therapeutics, Pfizer Inc., Prana Biotechnology Ltd., ReViva, Roche Labs, Sophiris, Sunovion, Targacept, Theravance, Transcept. Dr. Adler has received, in the last three years, the following: grant/research funds from Sunovian Pharmaceuticals, Purdue Pharmaceuticals, Enzymotec, Shire Pharmaceuticals, Theravance, Department of Veterans Affairs, Eli Lilly and Company, APSARD/Pound, Foundation; has been a consultant to Sunovian Pharmaceuticals, Enzymotec, Alcobra Pharmaceuticals, Theravance, National Football League, Major League Baseball, Shire Pharmaceuticals, Novartis Bioventures; and has received Royalty payments (as inventor) from NYU for license of adult ADHD scales and training materials since 2004.
Source: PubMed Central
Authors: Steven D Targum, Lenard A Adler
Institutions: Massachusetts General Hospital, New York University
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2294248407